{
    "xml": "<topic id=\"PHP104905\" outputclass=\"drug\" rev=\"1.7\" type=\"drug\" namespace=\"/drugs/peginterferon-beta-1a\" basename=\"peginterferon-beta-1a\" title=\"PEGINTERFERON BETA-1A\">\n<title>PEGINTERFERON BETA-1A</title>\n<body>\n<data name=\"vtmid\">27983711000001101</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_998292074\" title=\"Interferons\">Interferons</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n</body>\n<topic id=\"PHP104915\" outputclass=\"drugAction\" rev=\"1.10\" parent=\"/drugs/peginterferon-beta-1a\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Peginterferon beta-1a is a polyethylene glycol-conjugated ('pegylated') derivative of interferon beta; pegylation increases the persistence of interferon in the blood.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP104918\" outputclass=\"indicationsAndDose\" rev=\"1.15\" parent=\"/drugs/peginterferon-beta-1a\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of relapsing, remitting multiple sclerosis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP104913\" outputclass=\"contraindications\" rev=\"1.8\" parent=\"/drugs/peginterferon-beta-1a\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Severe depression</ph>; <ph outputclass=\"contraindication\">suicidal ideation</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP104911\" outputclass=\"cautions\" rev=\"1.12\" parent=\"/drugs/peginterferon-beta-1a\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">History of cardiac disorders</ph>; <ph outputclass=\"caution\">history of depressive disorders (avoid in severe depression or in those with suicidal ideation)</ph>; <ph outputclass=\"caution\">history of seizures</ph>; <ph outputclass=\"caution\">history of severe myelosupression</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p>Consult product literature for further information about cautions.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP104924\" outputclass=\"sideEffects\" rev=\"1.13\" parent=\"/drugs/peginterferon-beta-1a\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>Consult product literature for information about side effects.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP104912\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/peginterferon-beta-1a\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Effective contraception required during treatment&#8212;consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP104920\" outputclass=\"pregnancy\" parent=\"/drugs/peginterferon-beta-1a\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Do not initiate during pregnancy.</p>\n<p>Avoid unless potential benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP104910\" outputclass=\"breastFeeding\" parent=\"/drugs/peginterferon-beta-1a\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP104917\" outputclass=\"hepaticImpairment\" parent=\"/drugs/peginterferon-beta-1a\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Caution in severe hepatic impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP104922\" outputclass=\"renalImpairment\" parent=\"/drugs/peginterferon-beta-1a\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Caution in severe renal impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP104928\" outputclass=\"monitoringRequirements\" parent=\"/drugs/peginterferon-beta-1a\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor for signs of hepatic injury&#8212;hepatic failure has been reported rarely.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Thrombotic microangiopathy</p>\n<p>Patients should be monitored for clinical features of thrombotic microangiopathy (TMA), including thrombocytopenia, new onset hypertension, fever, central nervous system symptoms (e.g. confusion and paresis), and impaired renal function. Any signs of TMA should be investigated fully and, if diagnosed, interferon beta should be stopped immediately and treatment for TMA promptly initiated (consult product literature for details).</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Nephrotic syndrome</p>\n<p>Patients should also be monitored for signs and symptoms of nephrotic syndrome, including oedema, proteinuria, and impaired renal function&#8212;monitor renal function periodically. If nephrotic syndrome develops, treat promptly and consider stopping interferon beta treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP104905-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/peginterferon-beta-1a\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP104989\" title=\"Solution for injection\" namespace=\"/drugs/peginterferon-beta-1a/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP104989\" namespace=\"/drugs/peginterferon-beta-1a/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP104905",
    "outputclass": "drug",
    "rev": "1.7",
    "type": "drug",
    "namespace": "/drugs/peginterferon-beta-1a",
    "basename": "peginterferon-beta-1a",
    "title": "PEGINTERFERON BETA-1A",
    "vtmid": "27983711000001101",
    "drugClassification": [
        "Interferons"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Peginterferon beta-1a is a polyethylene glycol-conjugated ('pegylated') derivative of interferon beta; pegylation increases the persistence of interferon in the blood.",
                "html": "<p>Peginterferon beta-1a is a polyethylene glycol-conjugated ('pegylated') derivative of interferon beta; pegylation increases the persistence of interferon in the blood.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of relapsing, remitting multiple sclerosis",
                        "html": "Treatment of relapsing, remitting multiple sclerosis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature).",
                        "html": "<p>(consult product literature).</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Severe depression",
                "html": "Severe depression"
            },
            {
                "type": "contraindications",
                "textContent": "suicidal ideation",
                "html": "suicidal ideation"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "History of cardiac disorders",
                "html": "History of cardiac disorders"
            },
            {
                "type": "cautions",
                "textContent": "history of depressive disorders (avoid in severe depression or in those with suicidal ideation)",
                "html": "history of depressive disorders (avoid in severe depression or in those with suicidal ideation)"
            },
            {
                "type": "cautions",
                "textContent": "history of seizures",
                "html": "history of seizures"
            },
            {
                "type": "cautions",
                "textContent": "history of severe myelosupression",
                "html": "history of severe myelosupression"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "textContent": "Consult product literature for further information about cautions.",
                "html": "<p>Consult product literature for further information about cautions.</p>"
            }
        ]
    },
    "sideEffects": {
        "advice": [
            {
                "type": "advice",
                "textContent": "Consult product literature for information about side effects.",
                "html": "<p>Consult product literature for information about side effects.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Effective contraception required during treatment&#8212;consult product literature.",
                "html": "<p>Effective contraception required during treatment&#8212;consult product literature.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Do not initiate during pregnancy.\n\nAvoid unless potential benefit outweighs risk.",
                "html": "<p>Do not initiate during pregnancy.</p><p>Avoid unless potential benefit outweighs risk.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;no information available.",
                "html": "<p>Avoid&#8212;no information available.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Caution in severe hepatic impairment.",
                "html": "<p>Caution in severe hepatic impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Caution in severe renal impairment.",
                "html": "<p>Caution in severe renal impairment.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor for signs of hepatic injury&#8212;hepatic failure has been reported rarely.",
                "html": "<p>Monitor for signs of hepatic injury&#8212;hepatic failure has been reported rarely.</p>"
            },
            {
                "type": "patientParameters",
                "title": "Thrombotic microangiopathy",
                "textContent": "Patients should be monitored for clinical features of thrombotic microangiopathy (TMA), including thrombocytopenia, new onset hypertension, fever, central nervous system symptoms (e.g. confusion and paresis), and impaired renal function. Any signs of TMA should be investigated fully and, if diagnosed, interferon beta should be stopped immediately and treatment for TMA promptly initiated (consult product literature for details).",
                "html": "<p>Patients should be monitored for clinical features of thrombotic microangiopathy (TMA), including thrombocytopenia, new onset hypertension, fever, central nervous system symptoms (e.g. confusion and paresis), and impaired renal function. Any signs of TMA should be investigated fully and, if diagnosed, interferon beta should be stopped immediately and treatment for TMA promptly initiated (consult product literature for details).</p>"
            },
            {
                "type": "patientParameters",
                "title": "Nephrotic syndrome",
                "textContent": "Patients should also be monitored for signs and symptoms of nephrotic syndrome, including oedema, proteinuria, and impaired renal function&#8212;monitor renal function periodically. If nephrotic syndrome develops, treat promptly and consider stopping interferon beta treatment.",
                "html": "<p>Patients should also be monitored for signs and symptoms of nephrotic syndrome, including oedema, proteinuria, and impaired renal function&#8212;monitor renal function periodically. If nephrotic syndrome develops, treat promptly and consider stopping interferon beta treatment.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP104989",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP104989",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}